MEDA Angels is involved in investing within the healthcare sector, leveraging extensive networks to support portfolio companies, as self-described by the company.

MEDA Angels

Abbott develops and delivers health care technologies and products. The company focuses on various sectors of health care, including diagnostics and nutrition. Self-described as a provider of life-changing solutions.

Abbott

AEGIS is a venture studio that builds startups.

AEGIS

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Metric
Company Name	MEDA Angels	Abbott	AEGIS	Boston Scientific Corporation
Symbol				BSX
MSH ID	COM:MEDAANGELS	COM:ABBOTT	COM:AEGISVENTURES	COM:BOSTONSCIENTIFIC
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Financial Services & Finance	Healthcare & Health Services	Financial Services & Finance	Healthcare
Industry	Healthcare Investment	Medical Devices and Diagnostics	Venture Capital	Medical - Devices
Country	US	US	UNKNOWN	US
Stage
Employee Count		10.00K		48K
Website	medaangels.com	abbott.com	aegisventures.com	bostonscientific.com
LinkedIn
Founders

Metric
Market Cap		113.37B
Enterprise Value
Monthly Web Traffic	873.36K
Web Traffic Growth	-0.14
Valuation
Raised Capital

Metric
Revenue				14.24B
Revenue (LTM)
Revenue (NTM)
Gross Profit				9.89B
EBITDA				3.62B
Operating Income				2.34B
Net Income				1.59B
EPS				1.08
Diluted EPS				1.07
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.69
Operating Profit Margin				0.18
EBITDA Margin				0.25
Net Profit Margin				0.12
Return on Equity				0.10
Return on Assets				0.05
Return on Capital Employed				0.09

MEDA

COM:MEDAANGELS

MEDA Angels

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				77.02
P/B Ratio				5.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				8.52
EV Multiple				31.41

Metric
Days Sales Outstanding				55.74
Days Payables Outstanding				79.86
Days Inventory Outstanding				207.52
Operating Cycle				264.63
Cash Conversion Cycle				189.09
Asset Turnover				0.42

Metric
Operating Cash Flow				2.50B
Free Cash Flow				1.70B
Cash Flow to Debt				0.26
Operating Cash Flow/Sales				0.18
Free Cash Flow Yield				0.02

Metric
Cash & Equivalents				865M
Accounts Receivable				-238M
Inventory				2.48B
Goodwill				14.39B
Debt to Capitalization				0.36
Debt to Assets				0.27
Current Ratio				1.42
Quick Ratio				1.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.02
R&D to Revenue				0.10
SG&A to Revenue